Lurasidone
Lurasidone is an atypical antipsychotic medication classified under psycholeptics (ATC-N05) used to treat schizophrenia and bipolar depression. It works by blocking dopamine D2 receptors and serotonin 5HT2A receptors in the brain, helping to reduce psychotic symptoms and stabilize mood.
Lurasidone is an antipsychotic used for schizophrenia and bipolar depression that works by blocking dopamine and serotonin receptors.
This medication carries a boxed (black box) warning — the strongest type of FDA warning. Review the full prescribing information before use.
Key facts at a glance
- ATC
- N05AE05
- RxNorm
- 1040028
- Generic
- Lurasidone
- Class
- atc-n05
- Brands
- Latuda
- Availability
- rx
- Lactation
- unknown
- Routes
- oral
- Forms
- tablet
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Lurasidone is FDA-approved for the treatment of schizophrenia in adults and adolescents (ages 13-17), as well as for major depressive episodes associated with bipolar I disorder (bipolar depression) in adults and pediatric patients (ages 10-17). It may be used as monotherapy or in combination with lithium or valproate.
Lurasidone is an atypical antipsychotic that works primarily by antagonizing dopamine D2 receptors and serotonin 5HT2A receptors. This combination of receptor blockade is thought to be responsible for both its antipsychotic effects and its efficacy in treating bipolar depression, though the exact mechanism is not fully understood.
Common side effects include akathisia, somnolence, nausea, and parkinsonism. Lurasidone should be taken with food (at least 350 calories) for optimal absorption. It is contraindicated in patients with known hypersensitivity and should be used cautiously in elderly patients with dementia-related psychosis due to increased mortality risk. Regular monitoring of metabolic parameters is recommended during treatment.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy